Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ShanDong 250001, China.
Can Respir J. 2022 Mar 27;2022:8369521. doi: 10.1155/2022/8369521. eCollection 2022.
Blood eosinophil (EOS) has recently been recognized as a biomarker for chronic obstructive pulmonary disease (COPD) patients. However, few studies have concentrated on the stability of blood eosinophil counts (BEC), and those studies have produced varying results. With further research, we have found minor drawbacks and vulnerabilities that lead to the variability of the results. This paper enumerates several areas of relevant research with varying conclusions to further investigate the stability of BEC in COPD patients.
血液嗜酸性粒细胞(EOS)最近被认为是慢性阻塞性肺疾病(COPD)患者的生物标志物。然而,很少有研究集中在血液嗜酸性粒细胞计数(BEC)的稳定性上,而且这些研究的结果也不尽相同。通过进一步的研究,我们发现了一些导致结果变异性的小缺陷和弱点。本文列举了几个具有不同结论的相关研究领域,以进一步研究 COPD 患者 BEC 的稳定性。